• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Equity Analysis

VASRO GmbH > Press > Equity Analysis
VASRO GmbH

Using Independent Research to Boost IR Impact in Asia Listings and Global Capital

  • November 17, 2025
  • Unkategorisiert
Independent Research strengthens IR for Asia listings, building trust, transparency, and global capital access through objective analysis.
Continue Reading
VASRO GmbH

PPA-Preise für den Mittelstand: Wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren

  • September 5, 2025
  • Tech
PPA-Preise für den Mittelstand: Erfahre, wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren und welche Preisbereiche aktuell marktüblich sind.
Continue Reading
VASRO GmbH

Pharma Disruptors: Stock Valuation Rankings of the Next Generation of Drug Developers

  • July 17, 2025
  • Pharma & Biotech
Pharma-Disruptoren im Fokus: Welche Kennzahlen und Rankings sind für die Bewertung innovativer Arzneimittelentwickler und deren Aktien entscheidend?
Continue Reading
VASRO GmbH

Biotech Stock Valuation Models: Advanced Forecasting Techniques Explained

  • July 16, 2025
  • Pharma & Biotech
Biotech-Aktienbewertungsmodelle nutzen fortschrittliche Prognosetechniken, um Unsicherheiten, Risiken und Chancen im Biotech-Sektor präzise zu bewerten.
Continue Reading
VASRO GmbH

Convergence of Health Technology: Insights from the Equity Report on Digital Health Startups

  • July 15, 2025
  • Pharma & Biotech
Konvergenz der Gesundheitstechnologie: Wie digitale Gesundheits-Startups durch Innovation, Investitionen und neue Geschäftsmodelle laut Equity Report wachsen.
Continue Reading
VASRO GmbH

Top Equity Report Tools: Software and Data Platforms for Investors in 2025

  • July 14, 2025
  • Tech
Top-Aktienbericht-Tools 2025: Die besten Software-Lösungen und Datenplattformen für Investoren mit Fokus auf Analyse, Datenqualität und Sicherheit.
Continue Reading
VASRO GmbH

Essential Equity Analysis Indicators Every Pharma and Biotech Investor Should Know

  • June 26, 2025
  • Equity Analysis reports
Investors in pharmaceutical companies face a complex environment shaped by unique industry dynamics, where equity analysis relies on a blend of key indicators. These indicators include revenue growth, profitability,...
Continue Reading
VASRO GmbH

2025 Equity Report Essentials: AI-Driven Forecasts in Pharma, Biotech, and Tech

  • June 17, 2025
  • Pharma & Biotech, Tech
AI-driven forecasts in 2025 Equity Report Essentials reveal trends in pharma, biotech, and tech, offering insights into innovation, investment, and market shifts.
Continue Reading
VASRO GmbH

Analyzing Equity Reports: Key Takeaways for Pharma, Biotech, Tech, and Energy Investors

  • May 30, 2025
  • Energy, Pharma & Biotech, Tech
Analyze equity reports to uncover key insights for pharma, biotech, tech, and energy investments. Learn how sector trends and risks shape portfolio strategies.
Continue Reading
VASRO GmbH

Equity Report Breakdown: Sector-Wise Performance and Predictions

  • May 29, 2025
  • Unkategorisiert
Equity Report Breakdown reveals sector-wise trends, historical insights, and predictions to help you refine investment strategies and navigate market dynamics.
Continue Reading

Posts pagination

1 2 3 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.